Moreover, BBR inhibits the PD-1/PD-L1 pathway by inactivating CSN5 deubiquitination in non-small-cell lung carcinoma (NSCLC) and improves anti-cancer T-cell immunity (9). Here, COPS5 is linked to non-small cell lung carcinoma.